Pfizer Inc. with ticker code (PFE) have now 21 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $75.00 and $32.00 suggesting an average Analsyt target price of $40.10. Given that the stocks previous close was at $30.30 this indicates there is a potential upside of 32.3%. The 50 day moving average now sits at $31.74 while the 200 day moving average is $36.78. The company has a market capitalization of 171.20B. The stock price is currently at: $30.32 USD
The potential market cap would be $226,570,495,060 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 16.57, revenue per share of $12.16 and a 2.39% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
